Testing immune treatment after esophageal cancer therapy
Part of Cancer, Digestive system clinical trials.
This trial looks at how best to add an immunotherapy “extra” before, during, and after standard chemoradiation for stage II–III esophageal squamous cell cancer that can’t be operated on. It may help reduce cancer that remains after treatment by targeting immune cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old
- You have stage II–III esophageal squamous cell cancer confirmed by biopsy, and surgery isn’t an option
- Your planned treatment must include neoadjuvant immunochemotherapy, then chemoradiation (CCRT) with immunotherapy, then immunotherapy afterward
- Your day-to-day function score (ECOG) is 0 to 1 (fully active to limited but able to do most things)
- Your blood, liver, and kidney lab results are within required safety ranges
- You can sign informed consent, and if you can become pregnant you must have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a new approach before surgery: a short course of radiation (5 treatments) combined with chemotherapy and immunotherapy. The goal is to shrink the tumor and increase the chance of successful removal, while hopefully reducing side effects and improving long-term outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This study tests whether giving additional immunotherapy after esophageal cancer surgery can help prevent the cancer from coming back. If you've already had chemotherapy and immunotherapy before surgery, this trial may offer a way to continue that benefit after your operation.
This trial compares adding immunotherapy to standard chemo-radiation before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to improve how well the tumor responds and whether patients do better after surgery.
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.